Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

March 07, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

obligations may continue. See Instruction

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * SCHLEIFER LEONARD S

2. Issuer Name and Ticker or Trading

Symbol

REGENERON PHARMACEUTICALS INC

[REGN]

_X__ Director X_ Officer (give title

Issuer

10% Owner _ Other (specify

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year)

03/05/2013

below) President & CEO

777 OLD SAW MILL RIVER ROAD

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

TARRYTOWN, NY 10591

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secur	ities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit onor Dispos (Instr. 3,	(A)	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/24/2012		G V	59,271	D	\$ 0	242,087	D	
Common Stock	03/05/2013		S <u>(1)</u>	19,146	D	\$ 175.21 (2)	222,941	D	
Common Stock	03/06/2013		S <u>(1)</u>	60,803	D	\$ 175.28 (3)	162,138	D	
Common	03/06/2013		S <u>(1)</u>	8,200	D	\$ 176.1	153,938	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

(4) Stock \$ Common 03/07/2013 $S^{(1)}$ 3,534 D 175.13 150,404 D Stock Common By 401(k) 5,618 I Stock Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SCHLEIFER LEONARD S							
777 OLD SAW MILL RIVER ROAD	X		President & CEO				

Signatures

TARRYTOWN, NY 10591

/s/**Leonard S.
Schleifer

**Signature of Reporting Person

Date

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 19,146 shares of Company stock on March 5, 2013 at prices ranging from \$175.00 (2) to \$175.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 5, 2013 at each separate price.
- Represents volume-weighted average price of sales of 60,803 shares of Company stock on March 6, 2013 at prices ranging from \$175.00 (3) to \$175.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 6, 2013 at each separate price.
- Represents volume-weighted average price of sales of 8,200 shares of Company stock on March 6, 2013 at prices ranging from \$176.00 (4) to \$176.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 6, 2013 at each separate price.
- Represents volume-weighted average price of sales of 3,534 shares of Company stock on March 7, 2013 at prices ranging from \$175.00 (5) to \$175.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 7, 2013 at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.